JP6994941B2 - アンチセンス抗細菌性化合物および方法 - Google Patents

アンチセンス抗細菌性化合物および方法 Download PDF

Info

Publication number
JP6994941B2
JP6994941B2 JP2017535019A JP2017535019A JP6994941B2 JP 6994941 B2 JP6994941 B2 JP 6994941B2 JP 2017535019 A JP2017535019 A JP 2017535019A JP 2017535019 A JP2017535019 A JP 2017535019A JP 6994941 B2 JP6994941 B2 JP 6994941B2
Authority
JP
Japan
Prior art keywords
cpp
formula
compound
seq
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017535019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506272A (ja
JP2018506272A5 (enExample
Inventor
ブルース エル． ゲラー，
デイビッド グリーンバーグ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2018506272A publication Critical patent/JP2018506272A/ja
Publication of JP2018506272A5 publication Critical patent/JP2018506272A5/ja
Priority to JP2021202636A priority Critical patent/JP2022040131A/ja
Application granted granted Critical
Publication of JP6994941B2 publication Critical patent/JP6994941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017535019A 2014-12-31 2015-12-23 アンチセンス抗細菌性化合物および方法 Active JP6994941B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021202636A JP2022040131A (ja) 2014-12-31 2021-12-14 アンチセンス抗細菌性化合物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098713P 2014-12-31 2014-12-31
US62/098,713 2014-12-31
PCT/US2015/000280 WO2016108930A2 (en) 2014-12-31 2015-12-23 Antisense antibacterial compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021202636A Division JP2022040131A (ja) 2014-12-31 2021-12-14 アンチセンス抗細菌性化合物および方法

Publications (3)

Publication Number Publication Date
JP2018506272A JP2018506272A (ja) 2018-03-08
JP2018506272A5 JP2018506272A5 (enExample) 2019-02-07
JP6994941B2 true JP6994941B2 (ja) 2022-02-04

Family

ID=56285129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017535019A Active JP6994941B2 (ja) 2014-12-31 2015-12-23 アンチセンス抗細菌性化合物および方法
JP2021202636A Withdrawn JP2022040131A (ja) 2014-12-31 2021-12-14 アンチセンス抗細菌性化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021202636A Withdrawn JP2022040131A (ja) 2014-12-31 2021-12-14 アンチセンス抗細菌性化合物および方法

Country Status (7)

Country Link
US (1) US11293024B2 (enExample)
EP (1) EP3240794A4 (enExample)
JP (2) JP6994941B2 (enExample)
AU (1) AU2015372560B2 (enExample)
CA (1) CA2972653C (enExample)
HK (1) HK1246303A1 (enExample)
WO (1) WO2016108930A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3620178A3 (en) 2014-05-16 2020-07-22 Oregon State University Antisense antibacterial compounds and methods
US10391098B2 (en) 2014-05-19 2019-08-27 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
JP6994941B2 (ja) 2014-12-31 2022-02-04 オレゴン ステート ユニバーシティ アンチセンス抗細菌性化合物および方法
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2020035619A1 (en) * 2018-08-17 2020-02-20 Centre National De La Recherche Scientifique (Cnrs) Rna-based biocontrol methods to protect plants against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria
GB2579253A (en) 2018-11-28 2020-06-17 Pedanius Therapeutics Ltd Antibacterial antisense agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015265A1 (en) 1998-09-16 2000-03-23 Vitagenix, Inc. Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
WO2008008113A1 (en) 2006-07-13 2008-01-17 Avi Biopharma, Inc. Improved antibacterial antisense oligonucleotide and method
JP2010532168A (ja) 2007-06-29 2010-10-07 エーブイアイ バイオファーマ インコーポレイテッド 組織特異的ペプチドコンジュゲートおよび方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668616A (en) 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
JPH07501204A (ja) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
US5874500A (en) 1995-12-18 1999-02-23 Cohesion Technologies, Inc. Crosslinked polymer compositions and methods for their use
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
CA2289878A1 (en) 1997-05-02 1998-11-12 University Of Guelph Proteins involved in the synthesis and assembly of core lipopolysaccharide of pseudomonas aeruginosa
US20040033972A1 (en) 2000-12-20 2004-02-19 Horwitz Marcus A. Treatment of mycobacterium tuberculosis with antisense polynucleotides
US20060241075A1 (en) 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
WO2004093788A2 (en) 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
ES2367289T3 (es) 2004-07-02 2011-11-02 Avi Biopharma, Inc. Método y compuesto antibacteriano antisentido.
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
EP1915161B1 (en) 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007025016A1 (en) 2005-08-25 2007-03-01 Texas Tech University System Inhibition of metallo-beta-lactamase by double-stranded dna
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
WO2009064471A1 (en) 2007-11-15 2009-05-22 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009139635A1 (en) 2008-05-15 2009-11-19 Prosensa Technologies B.V. Polymyxin derivatives and uses thereof
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011018798A2 (en) 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
HUE030292T2 (en) 2010-09-30 2017-04-28 Nippon Shinyaku Co Ltd Morpholino-nucleic acid derivatives
EP3067420A1 (en) 2010-11-12 2016-09-14 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
US20120213663A1 (en) 2011-02-23 2012-08-23 King Fahd University Of Petroleum And Minerals Method of removing e. coli bacteria from an aqueous solution
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR102339196B1 (ko) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
KR101317263B1 (ko) 2011-07-05 2013-10-10 (주)지노첵 리얼타임 ｐｃｒ을 이용한 카바페넴 내성 장내균 검사 방법 및 키트
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
KR101450751B1 (ko) 2012-07-05 2014-10-16 서강대학교산학협력단 미생물을 이용한 지방산 제조 방법
EP3620178A3 (en) 2014-05-16 2020-07-22 Oregon State University Antisense antibacterial compounds and methods
US10391098B2 (en) 2014-05-19 2019-08-27 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
JP6994941B2 (ja) 2014-12-31 2022-02-04 オレゴン ステート ユニバーシティ アンチセンス抗細菌性化合物および方法
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015265A1 (en) 1998-09-16 2000-03-23 Vitagenix, Inc. Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
WO2008008113A1 (en) 2006-07-13 2008-01-17 Avi Biopharma, Inc. Improved antibacterial antisense oligonucleotide and method
JP2010532168A (ja) 2007-06-29 2010-10-07 エーブイアイ バイオファーマ インコーポレイテッド 組織特異的ペプチドコンジュゲートおよび方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy (2005) Vol.49, No.11, pp.4567-4575
Frontiers in Microbiology (2011) Vol.2, Article 118, pp.1-25
J. Med. Chem. (2000) Vol.43, pp.3085-3092
Journal of Antimicrobial Chemotherapy (2003) Vol.51, pp.531-543
Nucleic Acid Therapeutics (2012) Vol.22, No.5, pp.323-334
Nucleic Acids Research (2003) Vol.31, No.23, pp.6996-7002
PLOS ONE (2013) Vol.8, No.8, e71845, pp.1-16
PLOS ONE (2014) Vol.9, No.2, e89941, pp.1-11
Protein Expression and Purification (2001) Vol.21, pp.393-400

Also Published As

Publication number Publication date
WO2016108930A2 (en) 2016-07-07
JP2018506272A (ja) 2018-03-08
US20190169609A1 (en) 2019-06-06
CA2972653A1 (en) 2016-07-07
JP2022040131A (ja) 2022-03-10
AU2015372560A1 (en) 2017-07-20
WO2016108930A3 (en) 2016-08-25
CA2972653C (en) 2025-05-06
EP3240794A2 (en) 2017-11-08
US11293024B2 (en) 2022-04-05
EP3240794A4 (en) 2018-10-31
HK1246303A1 (zh) 2018-09-07
AU2015372560B2 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP6994941B2 (ja) アンチセンス抗細菌性化合物および方法
US11021706B2 (en) Antisense antibacterial compounds and methods
EP3569252B1 (en) Antisense antibacterial compounds and methods
US20210155934A1 (en) Antisense antibacterial compounds and methods
US12209240B2 (en) Antisense antibacterial compounds and methods
US20200283768A1 (en) Antisense antibacterial compounds and methods
WO2018161027A1 (en) Antisense antibacterial compounds and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211214

R150 Certificate of patent or registration of utility model

Ref document number: 6994941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250